Prot:ALXN1210-MG-306: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

Project: Research project

Project Details

StatusFinished
Effective start/end date1/17/20 → 1/17/23

Funding

  • INC Research, LLC (Prot:ALXN1210-MG-306)
  • Alexion Pharmaceuticals, Inc. (Prot:ALXN1210-MG-306)